- Conditions
- Breast Cancer
- Interventions
- Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
- Biological · Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 831
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- chemoprotection, complementary or alternative medicine procedure, management of therapy complications
- Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma
- Interventions
- rituximab, CHOP regimen, carmustine, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Myeloma, Non-Hodgkin's Lymphoma
- Interventions
- Meloxicam, Filgrastim
- Drug
- Lead sponsor
- Sherif S. Farag
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Stem Cell Transplant Complications, Hyperglycemia, Hypoglycemia
- Interventions
- Hematopoietic Stem Cell Transplant
- Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Alzheimer Disease
- Interventions
- HB-adMSCs
- Biological
- Lead sponsor
- Hope Biosciences LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hodgkin's Disease
- Interventions
- G-CSF Plus Plerixafor
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Rituximab (RTX), Tafasitamab, Bendamustine (BEN)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 18
- States / cities
- Anaheim, California • Bakersfield, California • Burbank, California + 15 more
- Conditions
- Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
- Interventions
- Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, in vitro-treated peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1994
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Sclerosis
- Interventions
- Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Lenalidomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Chronic Myeloproliferative Disorders
- Interventions
- filgrastim, busulfan, cytarabine, idarubicin, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 7
- States / cities
- Anchorage, Alaska • Tampa, Florida • Chicago, Illinois + 4 more
- Conditions
- Graft Versus Host Disease, Lymphoma
- Interventions
- aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- plerixafor
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Arsenic trioxide, Bortezomib, Melphalan, Autologous hematopoietic stem cell transplantation
- Drug · Biological
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- High-risk Diffuse Large B-cell Lymphoma
- Interventions
- Blinatumomab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Maywood, Illinois • Cleveland, Ohio + 1 more
- Conditions
- Acute Myeloid Leukemia, Measurable Residual Disease
- Interventions
- Motixafortide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Sarcoma, Neuroblastoma, Wilm's Tumor
- Interventions
- Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT)
- Biological · Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
- Interventions
- Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Aldesleukin, Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Sargramostim
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 30 Years
- Enrollment
- 1,449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2025
- U.S. locations
- 172
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 129 more